ABBOTT has secured an exclusive
license for several novel biomarkers
from Stanford University.
According to Abbott the novel
biomarkers will be used to aid in
the development of a molecular
diagnostic test which would
differentiate aggressive from
nonaggressive prostate cancer.
“Developing a clinically validated
prostate cancer prognostic assay
with actionable data represents the
'holy grail' in improving disease
management,” said Stanford
University Medical Centre’s James
Brooks, Associate Professor,
Department of Urology.The above article was sent to subscribers in Pharmacy Daily's issue from 18 Apr 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Apr 12
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.